Topiramate-associated sexual dysfunction: A systematic review
| Autor: | Melody Yun-Si Chen, Hsin-Ling Yin, Chia-Chang Chien, Louis Wei-Hsi Chen, Hung-Sheng Lin, Kuo-Yen Chen |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Topiramate Adult Male medicine.medical_specialty Pediatrics media_common.quotation_subject Libido Fructose Orgasm 03 medical and health sciences Behavioral Neuroscience Epilepsy 0302 clinical medicine Erectile Dysfunction medicine Humans Sexual Dysfunctions Psychological media_common Gynecology business.industry medicine.disease Anorgasmia in women Sexual Dysfunction Physiological 030104 developmental biology Erectile dysfunction Sexual dysfunction Neurology Anticonvulsants Female Neurology (clinical) medicine.symptom Sexual function business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Epilepsybehavior : EB. 73 |
| ISSN: | 1525-5069 |
| Popis: | Introduction Sexual pharmacotoxicity renders patients with epilepsy at a risk for sexual dysfunction (SD). This study is aimed to analyze the relationship between sexual function and topiramate to avoid topiramate-associated SD. Methods A systematic review following the PRISMA guidelines was performed to elucidate any SD occurrence in patients receiving topiramate. Results A total of 17 publications were reviewed. Based on limited polytherapy observational studies, the frequency of self-reported topiramate-associated SD, libido disorder, and orgasmic disorder in patients with polytherapy was 9.0%, 9.0%, and 2.6%, respectively (grade C evidence). Female patients mainly had anorgasmia, whereas male patients principally had erectile dysfunction. The daily dose of topiramate in patients with SD was within the recommended dose. Sexual adversity usually occurred from 4 weeks after topiramate use but favorably subsided without eventful complications after topiramate substitution or dose reduction in all patients. Conclusions Topiramate can elicit different patterns of SD, especially anorgasmia in women and erectile dysfunction in men, even with a therapeutic dose. Detailed drug education and careful monitoring are necessary to maximize sexual health, especially in persons undergoing polytherapy and with other risks for SD. Moreover, a rapid response, such as substitution or reduction of the dose, is suggested when SD occurs during its use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect